The following serious adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to PADCEV in combination with pembrolizumab at 1.25 mg/kg in 564 patients in EV-302 and EV-103 and PADCEV as a single agent at 1.25 mg/kg in 720 patients in EV-301, EV-201, EV-203 (NCT04995419), EV-101 (NCT02091999), and EV-102 (NCT03070990). Ocular disorders reflect 384 patients in EV-201, EV-101, and EV-102. Among 564 patients receiving PADCEV in combination with pembrolizumab, 59% were exposed for >6 months, and 24% were exposed for ≥12 months. In this pooled population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased alanine aminotransferase, decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection and decreased platelets. Among 720 patients receiving PADCEV as a single agent, 37% were exposed for >6 months, and 14% were exposed for ≥12 months. In this pooled population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased glucose, increased aspartate aminotransferase, decreased lymphocytes, increased creatinine, rash, fatigue, peripheral neuropathy, decreased albumin, decreased hemoglobin, alopecia, decreased appetite, decreased neutrophils, decreased sodium, increased alanine aminotransferase, decreased phosphate, diarrhea, nausea, pruritus, increased urate, dry eye, dysgeusia, constipation, increased lipase, decreased weight, decreased platelets, abdominal pain, dry skin.
The data described in the following section reflects exposure to PADCEV in combination with pembrolizumab from EV-302 and the dose escalation cohort, Cohort A and Cohort K of EV-103. Patients received PADCEV 1.25 mg/kg in combination with pembrolizumab until disease progression or unacceptable toxicity.
The data described in the following section also reflects exposure to PADCEV as a single agent from an open-label, randomized, trial (EV‑301) and Cohort 1 and Cohort 2 of an open-label, single arm, two cohort trial (EV-201). Patients received PADCEV 1.25 mg/kg until disease progression or unacceptable toxicity.
Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-302
The safety of PADCEV in combination with pembrolizumab was evaluated in an open-label, randomized, multicenter trial (EV-302) in patients with locally advanced or metastatic urothelial cancer. Patients received either PADCEV 1.25 mg/kg and pembrolizumab (n=440) or gemcitabine and platinum chemotherapy (either cisplatin or carboplatin) (n=433). Among patients who received PADCEV and pembrolizumab, the median duration of exposure for PADCEV was 7 months (range: 0.3 to 31.9 months).
Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions (≥2%) were rash (6%), acute kidney injury (5%), pneumonitis/ILD (4.5%), urinary tract infection (3.6%), diarrhea (3.2%) pneumonia (2.3%), pyrexia (2%), and hyperglycemia (2%).
Fatal adverse reactions occurred in 3.9% of patients treated with PADCEV in combination with pembrolizumab including acute respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis/ILD (0.2%).
Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were peripheral neuropathy (15%), rash (4.1%) and pneumonitis/ILD (2.3%).
Adverse reactions leading to dose interruption of PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were peripheral neuropathy (22%), rash (16%), COVID-19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased alanine aminotransferase (3%) and pruritus (2.5%).
Adverse reactions leading to dose reduction of PADCEV occurred in 42% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were rash (16%), peripheral neuropathy (13%) and fatigue (2.7%).
Table 3 summarizes the most common (≥15%) adverse reactions in EV-302.
Adverse Reaction | PADCEV in combination with pembrolizumab n=440 | Chemotherapy n=433 | ||
---|---|---|---|---|
All Grades % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| ||||
Skin and subcutaneous tissue disorders | ||||
Rash* | 68 | 15 | 15 | 0 |
Pruritus | 41 | 1.1 | 7 | 0 |
Alopecia | 35 | 0.5 | 8 | 0.2 |
Dry skin | 17 | 0.2 | 1 | 0 |
General disorders and administration site conditions | ||||
Fatigue* | 51 | 6 | 57 | 7 |
Pyrexia | 18 | 0.7 | 16 | 1.2 |
Nervous system disorders | ||||
Peripheral neuropathy* | 67 | 8 | 14 | 0 |
Dysgeusia | 21 | 0 | 9 | 0 |
Metabolism and nutrition disorders | ||||
Decreased appetite | 33 | 1.8 | 26 | 1.8 |
Gastrointestinal disorders | ||||
Diarrhea | 38 | 4.5 | 16 | 1.4 |
Nausea | 26 | 1.6 | 41 | 2.8 |
Constipation | 26 | 0 | 34 | 0.7 |
Investigations | ||||
Decreased weight | 33 | 3.6 | 9 | 0.2 |
Eye disorders | ||||
Dry eye* | 24 | 0 | 2.1 | 0 |
Infections and infestations | ||||
Urinary tract infection | 21 | 5 | 19 | 8 |
Clinically relevant adverse reactions (<15%) include vomiting (12%), pneumonitis/ILD (10%), hypothyroidism (10%), blurred vision (6%), infusion site extravasation (2%) and myositis (0.5%).
Laboratory Abnormality | PADCEV in combination with pembrolizumab | Chemotherapy | ||
---|---|---|---|---|
All Grades* % | Grade 3-4* % | All Grades* % | Grade 3-4* % | |
| ||||
Chemistry | ||||
Increased aspartate aminotransferase | 75 | 5 | 39 | 3 |
Increased creatinine | 71 | 3 | 68 | 3 |
Increased glucose | 66 | 14 | 54 | 5 |
Increased alanine aminotransferase | 59 | 5 | 49 | 3 |
Decreased sodium | 46 | 13 | 47 | 13 |
Decreased phosphate | 44 | 9 | 36 | 9 |
Decreased albumin | 39 | 2 | 35 | 0.5 |
Decreased potassium | 26 | 5 | 16 | 3 |
Increased potassium | 24 | 1 | 36 | 4 |
Increased calcium | 21 | 1 | 14 | 0.2 |
Hematology | ||||
Decreased lymphocytes | 58 | 15 | 59 | 17 |
Decreased hemoglobin | 53 | 7 | 89 | 33 |
Decreased neutrophils | 30 | 9 | 80 | 50 |
Previously Untreated Cisplatin Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer
EV-103
The safety of PADCEV was evaluated in combination with pembrolizumab in a multi cohort trial (EV-103) in 121 patients with locally advanced or metastatic urothelial cancer who were not eligible for cisplatin-containing chemotherapy and received at least one dose of PADCEV 1.25 mg/kg and pembrolizumab [see Clinical Studies (14)]. The median duration of exposure to PADCEV was 7 months (range: 0.6 to 33 months).
Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions (≥2%) were acute kidney injury (7%), urinary tract infection (7%), urosepsis (5%), sepsis (3.3%), pneumonia (3.3%), hematuria (3.3%), pneumonitis/ILD (3.3%), urinary retention (2.5%), diarrhea (2.5%), myasthenia gravis (2.5%), myositis (2.5%), anemia (2.5%), and hypotension (2.5%).
Fatal adverse reactions occurred in 5% of patients treated with PADCEV in combination with pembrolizumab including sepsis (1.6%), bullous dermatitis (0.8%), myasthenia gravis (0.8%), and pneumonitis/ILD (0.8%).
Adverse reactions leading to discontinuation of PADCEV occurred in 36% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were peripheral neuropathy (20%) and rash (6%).
Adverse reactions leading to dose interruption of PADCEV occurred in 69% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were peripheral neuropathy (18%), rash (12%), increased lipase (6%), pneumonitis/ILD (6%), diarrhea (4.1%), acute kidney injury (3.3%), increased alanine aminotransferase (3.3%), fatigue (3.3%), neutropenia (3.3%), urinary tract infection (3.3%), increased amylase (2.5%), anemia (2.5%), COVID-19 (2.5%), hyperglycemia (2.5%), and hypotension (2.5%).
Adverse reactions leading to dose reduction of PADCEV occurred in 45% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were peripheral neuropathy (17%), rash (12%), fatigue (5%), neutropenia (5%), and diarrhea (4.1%).
Table 5 summarizes the most common (≥20%) adverse reactions in EV-103.
Adverse Reaction | PADCEV in combination with pembrolizumab n=121 | |
---|---|---|
All Grades % | Grade 3-4 % | |
| ||
Skin and subcutaneous tissue disorders | ||
Rash* | 71 | 21 |
Alopecia | 52 | 0 |
Pruritus | 40 | 3.3 |
Dry skin | 21 | 0.8 |
Nervous system disorders | ||
Peripheral neuropathy* | 65 | 3.3 |
Dysgeusia | 35 | 0 |
Dizziness | 23 | 0 |
General disorders and administration site conditions | ||
Fatigue | 60 | 11 |
Peripheral edema | 26 | 0 |
Investigations | ||
Decreased weight | 48 | 5 |
Gastrointestinal disorders | ||
Diarrhea | 45 | 7 |
Nausea | 36 | 0.8 |
Constipation | 27 | 0 |
Metabolism and nutrition disorders | ||
Decreased appetite | 38 | 0.8 |
Infections and infestations | ||
Urinary tract infection | 30 | 12 |
Eye disorders | ||
Dry eye | 25 | 0 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 23 | 1.7 |
Clinically relevant adverse reactions (<20%) include vomiting (19.8%), pyrexia (18%), hypothyroidism (11%), pneumonitis/ILD (10%), myasthenia gravis (2.5%), myositis (3.3%), and infusion site extravasation (0.8%).
Laboratory Abnormality | PADCEV in combination with pembrolizumab | |
---|---|---|
All Grades* % | Grade 3-4* % | |
| ||
Chemistry | ||
Increased glucose | 74 | 13 |
Increased aspartate aminotransferase | 73 | 9 |
Increased creatinine | 69 | 3.3 |
Decreased sodium | 60 | 19 |
Increased alanine aminotransferase | 60 | 7 |
Increased lipase | 59 | 32 |
Decreased albumin | 59 | 4.2 |
Decreased phosphate | 51 | 15 |
Decreased potassium | 35 | 8 |
Increased potassium | 27 | 1.7 |
Increased calcium | 27 | 4.2 |
Hematology | ||
Decreased hemoglobin | 69 | 15 |
Decreased lymphocytes | 64 | 17 |
Decreased neutrophils | 32 | 12 |
Previously Treated Locally Advanced or Metastatic Urothelial Cancer
EV-301
The safety of PADCEV was evaluated as a single agent in EV-301 in patients with locally advanced or metastatic urothelial cancer (n=296) who received at least one dose of PADCEV 1.25 mg/kg and who were previously treated with a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy [see Clinical Studies (14)]. Routine ophthalmologic exams were not conducted in EV-301. The median duration of exposure to PADCEV was 5 months (range: 0.5 to 19 months).
Serious adverse reactions occurred in 47% of patients treated with PADCEV. The most common serious adverse reactions (≥2%) were urinary tract infection, acute kidney injury (7% each) and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis/ILD and pelvic abscess (0.3% each).
Adverse reactions leading to discontinuation occurred in 17% of patients; the most common adverse reactions (≥2%) leading to discontinuation were peripheral neuropathy (5%) and rash (4%).
Adverse reactions leading to dose interruption occurred in 61% of patients; the most common adverse reactions (≥4%) leading to dose interruption were peripheral neuropathy (23%), rash (11%) and fatigue (9%).
Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions (≥2%) leading to dose reduction were peripheral neuropathy (10%), rash (8%), decreased appetite (3%) and fatigue (3%).
Table 7 summarizes the most common (≥15%) adverse reactions in EV-301.
Adverse Reaction | PADCEV n=296 | Chemotherapy n=291 | ||
---|---|---|---|---|
All Grades % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| ||||
Skin and subcutaneous tissue disorders | ||||
Rash* | 54 | 14 | 20 | 0.3 |
Alopecia | 47 | 0 | 38 | 0 |
Pruritus | 34 | 2 | 7 | 0 |
Dry skin | 17 | 0 | 4 | 0 |
General disorders and administration site conditions | ||||
Fatigue* | 50 | 9 | 40 | 7 |
Pyrexia* | 22 | 2 | 14 | 0 |
Nervous system disorders | ||||
Peripheral neuropathy* | 50 | 5 | 34 | 3 |
Dysgeusia* | 26 | 0 | 8 | 0 |
Metabolism and nutrition disorders | ||||
Decreased appetite | 41 | 5 | 27 | 2 |
Gastrointestinal disorders | ||||
Diarrhea* | 35 | 4 | 23 | 2 |
Nausea | 30 | 1 | 25 | 2 |
Constipation | 28 | 1 | 25 | 2 |
Abdominal Pain* | 20 | 1 | 14 | 3 |
Musculoskeletal and connective tissue disorders | ||||
Musculoskeletal Pain* | 25 | 2 | 35 | 5 |
Eye Disorders | ||||
Dry eye* | 24 | 0.7 | 6 | 0.3 |
Infections and infestations | ||||
Urinary Tract Infection* | 17 | 6 | 13 | 3 |
Vascular disorders | ||||
Hemorrhage* | 17 | 3 | 13 | 2 |
Investigations | ||||
Decreased weight | 16 | 0.3 | 7 | 0 |
Clinically relevant adverse reactions (<15%) include vomiting (14%), increased aspartate aminotransferase (12%), hyperglycemia (10%), increased alanine aminotransferase (9%), pneumonitis/ILD (3%) and infusion site extravasation (0.7%).
Laboratory Abnormality | PADCEV* | Chemotherapy* | ||
---|---|---|---|---|
Grades 2-4 % | Grade 3-4 % | Grades 2-4 % | Grade 3-4 % | |
| ||||
Hematology | ||||
Decreased lymphocytes | 41 | 14 | 34 | 18 |
Decreased hemoglobin | 28 | 4 | 42 | 14 |
Decreased neutrophils | 27 | 12 | 25 | 17 |
Chemistry | ||||
Decreased phosphate | 39 | 8 | 24 | 6 |
Increased glucose (non-fasting) | 33 | 9 | 27 | 6 |
Increased creatinine | 18 | 2 | 13 | 0 |
Decreased potassium | 16 | 2 | 7 | 3 |
Increased lipase | 13 | 8 | 7 | 4 |
Decreased sodium | 8 | 8 | 5 | 5 |
EV-201, Cohort 1
The safety of PADCEV was evaluated as a single agent in EV-201, Cohort 1 in patients (n=125) with locally advanced or metastatic urothelial cancer who had received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [see Clinical Studies (14)]. Patients received PADCEV 1.25 mg/kg on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. The median duration of exposure to PADCEV was 4.6 months (range: 0.5-15.6).
Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (≥3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, sepsis and pneumonitis/ILD (each 0.8%).
Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%).
Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%).
Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).
Table 9 summarizes the All Grades and Grades 3-4 adverse reactions reported in patients in EV-201, Cohort 1.
Adverse Reaction | PADCEV n=125 | |
---|---|---|
All Grades % | Grade 3-4 % | |
| ||
General disorders and administration site conditions | ||
Fatigue* | 56 | 6 |
Nervous system disorders | ||
Peripheral neuropathy* | 56 | 4 |
Dysgeusia | 42 | 0 |
Metabolism and nutrition disorders | ||
Decreased appetite | 52 | 2 |
Skin and subcutaneous tissue disorders | ||
Rash* | 52 | 13 |
Alopecia | 50 | 0 |
Dry skin | 26 | 0 |
Pruritus* | 26 | 2 |
Gastrointestinal disorders | ||
Nausea | 45 | 3 |
Diarrhea* | 42 | 6 |
Vomiting | 18 | 2 |
Eye disorders | ||
Dry eye* | 40 | 0 |
Clinically relevant adverse reactions (<15%) include herpes zoster (3%), pneumonitis/ILD (2%) and infusion site extravasation (2%).
Laboratory Abnormality | PADCEV | |
---|---|---|
Grades 2-4* % | Grade 3-4* % | |
Hematology | ||
Decreased hemoglobin | 34 | 10 |
Decreased lymphocytes | 32 | 10 |
Decreased neutrophils | 14 | 5 |
Chemistry | ||
Decreased phosphate | 34 | 10 |
Increased glucose (non-fasting) | 27 | 8 |
Increased creatinine | 20 | 2 |
Decreased potassium | 19† | 1 |
Increased lipase | 14 | 9 |
Decreased sodium | 8 | 8 |
Increased urate | 7 | 7 |
EV-201, Cohort 2
The safety of PADCEV was evaluated as a single agent in EV-201, Cohort 2 in patients with locally advanced or metastatic urothelial cancer (n=89) who received at least one dose of PADCEV 1.25 mg/kg and had prior treatment with a PD-1 or PD-L1 inhibitor and were not eligible for cisplatin-based chemotherapy. The median duration of exposure was 5.98 months (range: 0.3 to 24.6 months).
Serious adverse reactions occurred in 39% of patients treated with PADCEV. The most common serious adverse reactions (≥3%) were pneumonia, sepsis and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia and pneumonitis/ILD (1.1% each).
Adverse reactions leading to discontinuation occurred in 20% of patients; the most common adverse reaction (≥2%) leading to discontinuation was peripheral neuropathy (7%).
Adverse reactions leading to dose interruption occurred in 60% of patients; the most common adverse reactions (≥3%) leading to dose interruption were peripheral neuropathy (19%), rash (9%), fatigue (8%), diarrhea (5%), increased aspartate aminotransferase (3%) and hyperglycemia (3%).
Adverse reactions leading to dose reduction occurred in 49% of patients; the most common adverse reactions (≥3%) leading to dose reduction were peripheral neuropathy (19%), rash (11%) and fatigue (7%).
Table 11 summarizes the All Grades and Grades 3-4 adverse reactions reported in patients in EV-201, Cohort 2.
Adverse Reaction | PADCEV n=89 | |
---|---|---|
All Grades (%) | Grades 3-4 (%) | |
| ||
Skin and subcutaneous tissue disorders | ||
Rash* | 66 | 17 |
Alopecia | 53 | 0 |
Pruritus | 35 | 3 |
Dry skin | 19 | 1 |
Nervous system disorders | ||
Peripheral neuropathy* | 58 | 8 |
Dysgeusia* | 29 | 0 |
General disorders and administration site conditions | ||
Fatigue* | 48 | 11 |
Metabolism and nutrition disorders | ||
Decreased appetite | 40 | 6 |
Hyperglycemia | 16 | 9 |
Gastrointestinal disorders | ||
Diarrhea* | 36 | 8 |
Nausea | 30 | 1 |
Investigations | ||
Decreased weight | 35 | 1 |
Eye disorders | ||
Dry eye* | 30 | 0 |
Clinically relevant adverse reactions (<15%) include vomiting (13%), increased aspartate aminotransferase (12%), increased lipase (11%), increased alanine aminotransferase (10%), pneumonitis/ILD (4%) and infusion site extravasation (1%).
| ||
Laboratory Abnormality | PADCEV n=88* | |
Grades 2-4* % | Grade 3-4* % | |
Hematology | ||
Decreased lymphocytes | 43 | 15 |
Decreased hemoglobin | 34 | 5 |
Decreased neutrophils | 20 | 9 |
Chemistry | ||
Increased glucose (non-fasting) | 36 | 13 |
Decreased phosphate | 25 | 7 |
Increased creatinine | 23 | 3 |
Increased lipase | 18 | 11 |
Increased urate | 9 | 9 |
Increased potassium | 8 | 6 |
Decreased sodium | 7 | 7 |
The following adverse reactions have been identified during post-approval use of PADCEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and subcutaneous tissue disorders: Epidermal necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis [see Warnings and Precautions (5.1)].
The following serious adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to PADCEV in combination with pembrolizumab at 1.25 mg/kg in 564 patients in EV-302 and EV-103 and PADCEV as a single agent at 1.25 mg/kg in 720 patients in EV-301, EV-201, EV-203 (NCT04995419), EV-101 (NCT02091999), and EV-102 (NCT03070990). Ocular disorders reflect 384 patients in EV-201, EV-101, and EV-102. Among 564 patients receiving PADCEV in combination with pembrolizumab, 59% were exposed for >6 months, and 24% were exposed for ≥12 months. In this pooled population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased alanine aminotransferase, decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection and decreased platelets. Among 720 patients receiving PADCEV as a single agent, 37% were exposed for >6 months, and 14% were exposed for ≥12 months. In this pooled population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased glucose, increased aspartate aminotransferase, decreased lymphocytes, increased creatinine, rash, fatigue, peripheral neuropathy, decreased albumin, decreased hemoglobin, alopecia, decreased appetite, decreased neutrophils, decreased sodium, increased alanine aminotransferase, decreased phosphate, diarrhea, nausea, pruritus, increased urate, dry eye, dysgeusia, constipation, increased lipase, decreased weight, decreased platelets, abdominal pain, dry skin.
The data described in the following section reflects exposure to PADCEV in combination with pembrolizumab from EV-302 and the dose escalation cohort, Cohort A and Cohort K of EV-103. Patients received PADCEV 1.25 mg/kg in combination with pembrolizumab until disease progression or unacceptable toxicity.
The data described in the following section also reflects exposure to PADCEV as a single agent from an open-label, randomized, trial (EV‑301) and Cohort 1 and Cohort 2 of an open-label, single arm, two cohort trial (EV-201). Patients received PADCEV 1.25 mg/kg until disease progression or unacceptable toxicity.
Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-302
The safety of PADCEV in combination with pembrolizumab was evaluated in an open-label, randomized, multicenter trial (EV-302) in patients with locally advanced or metastatic urothelial cancer. Patients received either PADCEV 1.25 mg/kg and pembrolizumab (n=440) or gemcitabine and platinum chemotherapy (either cisplatin or carboplatin) (n=433). Among patients who received PADCEV and pembrolizumab, the median duration of exposure for PADCEV was 7 months (range: 0.3 to 31.9 months).
Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions (≥2%) were rash (6%), acute kidney injury (5%), pneumonitis/ILD (4.5%), urinary tract infection (3.6%), diarrhea (3.2%) pneumonia (2.3%), pyrexia (2%), and hyperglycemia (2%).
Fatal adverse reactions occurred in 3.9% of patients treated with PADCEV in combination with pembrolizumab including acute respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis/ILD (0.2%).
Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were peripheral neuropathy (15%), rash (4.1%) and pneumonitis/ILD (2.3%).
Adverse reactions leading to dose interruption of PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were peripheral neuropathy (22%), rash (16%), COVID-19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased alanine aminotransferase (3%) and pruritus (2.5%).
Adverse reactions leading to dose reduction of PADCEV occurred in 42% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were rash (16%), peripheral neuropathy (13%) and fatigue (2.7%).
Table 3 summarizes the most common (≥15%) adverse reactions in EV-302.
Adverse Reaction | PADCEV in combination with pembrolizumab n=440 | Chemotherapy n=433 | ||
---|---|---|---|---|
All Grades % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| ||||
Skin and subcutaneous tissue disorders | ||||
Rash* | 68 | 15 | 15 | 0 |
Pruritus | 41 | 1.1 | 7 | 0 |
Alopecia | 35 | 0.5 | 8 | 0.2 |
Dry skin | 17 | 0.2 | 1 | 0 |
General disorders and administration site conditions | ||||
Fatigue* | 51 | 6 | 57 | 7 |
Pyrexia | 18 | 0.7 | 16 | 1.2 |
Nervous system disorders | ||||
Peripheral neuropathy* | 67 | 8 | 14 | 0 |
Dysgeusia | 21 | 0 | 9 | 0 |
Metabolism and nutrition disorders | ||||
Decreased appetite | 33 | 1.8 | 26 | 1.8 |
Gastrointestinal disorders | ||||
Diarrhea | 38 | 4.5 | 16 | 1.4 |
Nausea | 26 | 1.6 | 41 | 2.8 |
Constipation | 26 | 0 | 34 | 0.7 |
Investigations | ||||
Decreased weight | 33 | 3.6 | 9 | 0.2 |
Eye disorders | ||||
Dry eye* | 24 | 0 | 2.1 | 0 |
Infections and infestations | ||||
Urinary tract infection | 21 | 5 | 19 | 8 |
Clinically relevant adverse reactions (<15%) include vomiting (12%), pneumonitis/ILD (10%), hypothyroidism (10%), blurred vision (6%), infusion site extravasation (2%) and myositis (0.5%).
Laboratory Abnormality | PADCEV in combination with pembrolizumab | Chemotherapy | ||
---|---|---|---|---|
All Grades* % | Grade 3-4* % | All Grades* % | Grade 3-4* % | |
| ||||
Chemistry | ||||
Increased aspartate aminotransferase | 75 | 5 | 39 | 3 |
Increased creatinine | 71 | 3 | 68 | 3 |
Increased glucose | 66 | 14 | 54 | 5 |
Increased alanine aminotransferase | 59 | 5 | 49 | 3 |
Decreased sodium | 46 | 13 | 47 | 13 |
Decreased phosphate | 44 | 9 | 36 | 9 |
Decreased albumin | 39 | 2 | 35 | 0.5 |
Decreased potassium | 26 | 5 | 16 | 3 |
Increased potassium | 24 | 1 | 36 | 4 |
Increased calcium | 21 | 1 | 14 | 0.2 |
Hematology | ||||
Decreased lymphocytes | 58 | 15 | 59 | 17 |
Decreased hemoglobin | 53 | 7 | 89 | 33 |
Decreased neutrophils | 30 | 9 | 80 | 50 |
Previously Untreated Cisplatin Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer
EV-103
The safety of PADCEV was evaluated in combination with pembrolizumab in a multi cohort trial (EV-103) in 121 patients with locally advanced or metastatic urothelial cancer who were not eligible for cisplatin-containing chemotherapy and received at least one dose of PADCEV 1.25 mg/kg and pembrolizumab [see Clinical Studies (14)]. The median duration of exposure to PADCEV was 7 months (range: 0.6 to 33 months).
Serious adverse reactions occurred in 50% of patients treated with PADCEV in combination with pembrolizumab. The most common serious adverse reactions (≥2%) were acute kidney injury (7%), urinary tract infection (7%), urosepsis (5%), sepsis (3.3%), pneumonia (3.3%), hematuria (3.3%), pneumonitis/ILD (3.3%), urinary retention (2.5%), diarrhea (2.5%), myasthenia gravis (2.5%), myositis (2.5%), anemia (2.5%), and hypotension (2.5%).
Fatal adverse reactions occurred in 5% of patients treated with PADCEV in combination with pembrolizumab including sepsis (1.6%), bullous dermatitis (0.8%), myasthenia gravis (0.8%), and pneumonitis/ILD (0.8%).
Adverse reactions leading to discontinuation of PADCEV occurred in 36% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were peripheral neuropathy (20%) and rash (6%).
Adverse reactions leading to dose interruption of PADCEV occurred in 69% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were peripheral neuropathy (18%), rash (12%), increased lipase (6%), pneumonitis/ILD (6%), diarrhea (4.1%), acute kidney injury (3.3%), increased alanine aminotransferase (3.3%), fatigue (3.3%), neutropenia (3.3%), urinary tract infection (3.3%), increased amylase (2.5%), anemia (2.5%), COVID-19 (2.5%), hyperglycemia (2.5%), and hypotension (2.5%).
Adverse reactions leading to dose reduction of PADCEV occurred in 45% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were peripheral neuropathy (17%), rash (12%), fatigue (5%), neutropenia (5%), and diarrhea (4.1%).
Table 5 summarizes the most common (≥20%) adverse reactions in EV-103.
Adverse Reaction | PADCEV in combination with pembrolizumab n=121 | |
---|---|---|
All Grades % | Grade 3-4 % | |
| ||
Skin and subcutaneous tissue disorders | ||
Rash* | 71 | 21 |
Alopecia | 52 | 0 |
Pruritus | 40 | 3.3 |
Dry skin | 21 | 0.8 |
Nervous system disorders | ||
Peripheral neuropathy* | 65 | 3.3 |
Dysgeusia | 35 | 0 |
Dizziness | 23 | 0 |
General disorders and administration site conditions | ||
Fatigue | 60 | 11 |
Peripheral edema | 26 | 0 |
Investigations | ||
Decreased weight | 48 | 5 |
Gastrointestinal disorders | ||
Diarrhea | 45 | 7 |
Nausea | 36 | 0.8 |
Constipation | 27 | 0 |
Metabolism and nutrition disorders | ||
Decreased appetite | 38 | 0.8 |
Infections and infestations | ||
Urinary tract infection | 30 | 12 |
Eye disorders | ||
Dry eye | 25 | 0 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 23 | 1.7 |
Clinically relevant adverse reactions (<20%) include vomiting (19.8%), pyrexia (18%), hypothyroidism (11%), pneumonitis/ILD (10%), myasthenia gravis (2.5%), myositis (3.3%), and infusion site extravasation (0.8%).
Laboratory Abnormality | PADCEV in combination with pembrolizumab | |
---|---|---|
All Grades* % | Grade 3-4* % | |
| ||
Chemistry | ||
Increased glucose | 74 | 13 |
Increased aspartate aminotransferase | 73 | 9 |
Increased creatinine | 69 | 3.3 |
Decreased sodium | 60 | 19 |
Increased alanine aminotransferase | 60 | 7 |
Increased lipase | 59 | 32 |
Decreased albumin | 59 | 4.2 |
Decreased phosphate | 51 | 15 |
Decreased potassium | 35 | 8 |
Increased potassium | 27 | 1.7 |
Increased calcium | 27 | 4.2 |
Hematology | ||
Decreased hemoglobin | 69 | 15 |
Decreased lymphocytes | 64 | 17 |
Decreased neutrophils | 32 | 12 |
Previously Treated Locally Advanced or Metastatic Urothelial Cancer
EV-301
The safety of PADCEV was evaluated as a single agent in EV-301 in patients with locally advanced or metastatic urothelial cancer (n=296) who received at least one dose of PADCEV 1.25 mg/kg and who were previously treated with a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy [see Clinical Studies (14)]. Routine ophthalmologic exams were not conducted in EV-301. The median duration of exposure to PADCEV was 5 months (range: 0.5 to 19 months).
Serious adverse reactions occurred in 47% of patients treated with PADCEV. The most common serious adverse reactions (≥2%) were urinary tract infection, acute kidney injury (7% each) and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis/ILD and pelvic abscess (0.3% each).
Adverse reactions leading to discontinuation occurred in 17% of patients; the most common adverse reactions (≥2%) leading to discontinuation were peripheral neuropathy (5%) and rash (4%).
Adverse reactions leading to dose interruption occurred in 61% of patients; the most common adverse reactions (≥4%) leading to dose interruption were peripheral neuropathy (23%), rash (11%) and fatigue (9%).
Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions (≥2%) leading to dose reduction were peripheral neuropathy (10%), rash (8%), decreased appetite (3%) and fatigue (3%).
Table 7 summarizes the most common (≥15%) adverse reactions in EV-301.
Adverse Reaction | PADCEV n=296 | Chemotherapy n=291 | ||
---|---|---|---|---|
All Grades % | Grade 3-4 % | All Grades % | Grade 3-4 % | |
| ||||
Skin and subcutaneous tissue disorders | ||||
Rash* | 54 | 14 | 20 | 0.3 |
Alopecia | 47 | 0 | 38 | 0 |
Pruritus | 34 | 2 | 7 | 0 |
Dry skin | 17 | 0 | 4 | 0 |
General disorders and administration site conditions | ||||
Fatigue* | 50 | 9 | 40 | 7 |
Pyrexia* | 22 | 2 | 14 | 0 |
Nervous system disorders | ||||
Peripheral neuropathy* | 50 | 5 | 34 | 3 |
Dysgeusia* | 26 | 0 | 8 | 0 |
Metabolism and nutrition disorders | ||||
Decreased appetite | 41 | 5 | 27 | 2 |
Gastrointestinal disorders | ||||
Diarrhea* | 35 | 4 | 23 | 2 |
Nausea | 30 | 1 | 25 | 2 |
Constipation | 28 | 1 | 25 | 2 |
Abdominal Pain* | 20 | 1 | 14 | 3 |
Musculoskeletal and connective tissue disorders | ||||
Musculoskeletal Pain* | 25 | 2 | 35 | 5 |
Eye Disorders | ||||
Dry eye* | 24 | 0.7 | 6 | 0.3 |
Infections and infestations | ||||
Urinary Tract Infection* | 17 | 6 | 13 | 3 |
Vascular disorders | ||||
Hemorrhage* | 17 | 3 | 13 | 2 |
Investigations | ||||
Decreased weight | 16 | 0.3 | 7 | 0 |
Clinically relevant adverse reactions (<15%) include vomiting (14%), increased aspartate aminotransferase (12%), hyperglycemia (10%), increased alanine aminotransferase (9%), pneumonitis/ILD (3%) and infusion site extravasation (0.7%).
Laboratory Abnormality | PADCEV* | Chemotherapy* | ||
---|---|---|---|---|
Grades 2-4 % | Grade 3-4 % | Grades 2-4 % | Grade 3-4 % | |
| ||||
Hematology | ||||
Decreased lymphocytes | 41 | 14 | 34 | 18 |
Decreased hemoglobin | 28 | 4 | 42 | 14 |
Decreased neutrophils | 27 | 12 | 25 | 17 |
Chemistry | ||||
Decreased phosphate | 39 | 8 | 24 | 6 |
Increased glucose (non-fasting) | 33 | 9 | 27 | 6 |
Increased creatinine | 18 | 2 | 13 | 0 |
Decreased potassium | 16 | 2 | 7 | 3 |
Increased lipase | 13 | 8 | 7 | 4 |
Decreased sodium | 8 | 8 | 5 | 5 |
EV-201, Cohort 1
The safety of PADCEV was evaluated as a single agent in EV-201, Cohort 1 in patients (n=125) with locally advanced or metastatic urothelial cancer who had received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [see Clinical Studies (14)]. Patients received PADCEV 1.25 mg/kg on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. The median duration of exposure to PADCEV was 4.6 months (range: 0.5-15.6).
Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (≥3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, sepsis and pneumonitis/ILD (each 0.8%).
Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%).
Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%).
Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).
Table 9 summarizes the All Grades and Grades 3-4 adverse reactions reported in patients in EV-201, Cohort 1.
Adverse Reaction | PADCEV n=125 | |
---|---|---|
All Grades % | Grade 3-4 % | |
| ||
General disorders and administration site conditions | ||
Fatigue* | 56 | 6 |
Nervous system disorders | ||
Peripheral neuropathy* | 56 | 4 |
Dysgeusia | 42 | 0 |
Metabolism and nutrition disorders | ||
Decreased appetite | 52 | 2 |
Skin and subcutaneous tissue disorders | ||
Rash* | 52 | 13 |
Alopecia | 50 | 0 |
Dry skin | 26 | 0 |
Pruritus* | 26 | 2 |
Gastrointestinal disorders | ||
Nausea | 45 | 3 |
Diarrhea* | 42 | 6 |
Vomiting | 18 | 2 |
Eye disorders | ||
Dry eye* | 40 | 0 |
Clinically relevant adverse reactions (<15%) include herpes zoster (3%), pneumonitis/ILD (2%) and infusion site extravasation (2%).
Laboratory Abnormality | PADCEV | |
---|---|---|
Grades 2-4* % | Grade 3-4* % | |
Hematology | ||
Decreased hemoglobin | 34 | 10 |
Decreased lymphocytes | 32 | 10 |
Decreased neutrophils | 14 | 5 |
Chemistry | ||
Decreased phosphate | 34 | 10 |
Increased glucose (non-fasting) | 27 | 8 |
Increased creatinine | 20 | 2 |
Decreased potassium | 19† | 1 |
Increased lipase | 14 | 9 |
Decreased sodium | 8 | 8 |
Increased urate | 7 | 7 |
EV-201, Cohort 2
The safety of PADCEV was evaluated as a single agent in EV-201, Cohort 2 in patients with locally advanced or metastatic urothelial cancer (n=89) who received at least one dose of PADCEV 1.25 mg/kg and had prior treatment with a PD-1 or PD-L1 inhibitor and were not eligible for cisplatin-based chemotherapy. The median duration of exposure was 5.98 months (range: 0.3 to 24.6 months).
Serious adverse reactions occurred in 39% of patients treated with PADCEV. The most common serious adverse reactions (≥3%) were pneumonia, sepsis and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia and pneumonitis/ILD (1.1% each).
Adverse reactions leading to discontinuation occurred in 20% of patients; the most common adverse reaction (≥2%) leading to discontinuation was peripheral neuropathy (7%).
Adverse reactions leading to dose interruption occurred in 60% of patients; the most common adverse reactions (≥3%) leading to dose interruption were peripheral neuropathy (19%), rash (9%), fatigue (8%), diarrhea (5%), increased aspartate aminotransferase (3%) and hyperglycemia (3%).
Adverse reactions leading to dose reduction occurred in 49% of patients; the most common adverse reactions (≥3%) leading to dose reduction were peripheral neuropathy (19%), rash (11%) and fatigue (7%).
Table 11 summarizes the All Grades and Grades 3-4 adverse reactions reported in patients in EV-201, Cohort 2.
Adverse Reaction | PADCEV n=89 | |
---|---|---|
All Grades (%) | Grades 3-4 (%) | |
| ||
Skin and subcutaneous tissue disorders | ||
Rash* | 66 | 17 |
Alopecia | 53 | 0 |
Pruritus | 35 | 3 |
Dry skin | 19 | 1 |
Nervous system disorders | ||
Peripheral neuropathy* | 58 | 8 |
Dysgeusia* | 29 | 0 |
General disorders and administration site conditions | ||
Fatigue* | 48 | 11 |
Metabolism and nutrition disorders | ||
Decreased appetite | 40 | 6 |
Hyperglycemia | 16 | 9 |
Gastrointestinal disorders | ||
Diarrhea* | 36 | 8 |
Nausea | 30 | 1 |
Investigations | ||
Decreased weight | 35 | 1 |
Eye disorders | ||
Dry eye* | 30 | 0 |
Clinically relevant adverse reactions (<15%) include vomiting (13%), increased aspartate aminotransferase (12%), increased lipase (11%), increased alanine aminotransferase (10%), pneumonitis/ILD (4%) and infusion site extravasation (1%).
| ||
Laboratory Abnormality | PADCEV n=88* | |
Grades 2-4* % | Grade 3-4* % | |
Hematology | ||
Decreased lymphocytes | 43 | 15 |
Decreased hemoglobin | 34 | 5 |
Decreased neutrophils | 20 | 9 |
Chemistry | ||
Increased glucose (non-fasting) | 36 | 13 |
Decreased phosphate | 25 | 7 |
Increased creatinine | 23 | 3 |
Increased lipase | 18 | 11 |
Increased urate | 9 | 9 |
Increased potassium | 8 | 6 |
Decreased sodium | 7 | 7 |
The following adverse reactions have been identified during post-approval use of PADCEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and subcutaneous tissue disorders: Epidermal necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis [see Warnings and Precautions (5.1)].
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.